N.E.W. Advisory Services’s Oramed Pharmaceuticals ORMP Stock Holding History

N.E.W. Advisory Services’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.5K	Hold	3,429	–	–	﹤0.01%	565
2026 Q1	$11.7K	Buy	3,429 +229	+7%	+$777	﹤0.01%	598
2025 Q4	$9.12K	Buy	+3,200	New	+$8.25K	﹤0.01%	630
2025 Q2	–	Sell	-18,900	Closed	-$40.4K	–	897
2025 Q1	$40.4K	Buy	18,900 +6,540	+53%	+$15.1K	﹤0.01%	390
2024 Q4	$29.9K	Hold	12,360	–	–	﹤0.01%	187
2024 Q3	$30.2K	Hold	12,360	–	–	﹤0.01%	183
2024 Q2	$31.8K	Sell	12,360 -600	-5%	-$1.43K	﹤0.01%	180
2024 Q1	$37.8K	Hold	12,960	–	–	﹤0.01%	172
2023 Q4	$29.9K	Hold	12,960	–	–	﹤0.01%	162
2023 Q3	$33.8K	Buy	+12,960	New	+$40.8K	﹤0.01%	151

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

N.E.W. Advisory Services's ORMP Position: Q2 2026 in Review

N.E.W. Advisory Services held its Oramed Pharmaceuticals (ORMP) position steady in Q2 2026 at 3,429 shares worth $16.5K. The position accounts for ﹤0.01% of the portfolio, ranked #565.

N.E.W. Advisory Services first reported a position in ORMP in Q3 2023 and has held it in 10 quarters since. The position peaked at $40.4K in Q1 2025. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

N.E.W. Advisory Services held 3,429 shares of Oramed Pharmaceuticals worth $16.5K as of Q2 2026.
N.E.W. Advisory Services left its Oramed Pharmaceuticals share count unchanged in Q2 2026.
Oramed Pharmaceuticals made up ﹤0.01% of N.E.W. Advisory Services's portfolio in Q2 2026, its #565 holding.
N.E.W. Advisory Services first reported a position in Oramed Pharmaceuticals in Q3 2023 and has held it in 10 quarters since.
N.E.W. Advisory Services's Oramed Pharmaceuticals position peaked at $40.4K in Q1 2025.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on N.E.W. Advisory Services's 13F filing for Q2 2026, filed 6 Aug 2026.